معرفی
Zhou Xi Kathy is a Professor of Research in Population Health Sciences at Weill Cornell Medical College. Her work integrates cancer biology, immunology, and clinical translation with a focus on breast, prostate, and colorectal cancers.
Education
- B.S., Nanjing University (China), 1996
- M.S., Duke University, 2000
- Ph.D., Duke University, 2002
Research Interests
Dr. Zhou’s laboratory investigates the intersection of obesity, inflammation, and cancer. She explores how adipose tissue inflammation drives tumorigenesis and therapeutic resistance in hormone-receptor-positive breast cancer and how radiotherapy can be optimized in combination with immunotherapy. Additional interests include the tumor microenvironment, gut microbiome interactions, and metabolic reprogramming in prostate and colorectal cancers. Cutting-edge techniques such as 4D proteomics and super-resolution microscopy are leveraged for biomarker discovery in early pancreatic cancer detection.
Publication Trends
Her recent publications (2023–2025) emphasize translational studies combining radiotherapy with immune checkpoint inhibitors, dissecting resistance mechanisms to CDK4/6 inhibitors, and elucidating the role of γδ T cells and macrophage populations in breast cancer. Large-scale genomic and metabolomic analyses support biomarker-driven clinical trials, while preclinical mouse models guide dose-fractionation strategies in both breast and prostate radiotherapy.
Active Grants & Funding
- NCI Co-Investigator: "Role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer" (2025–2030)
- Pershing Square Foundation Co-Investigator: "Targeting Ovarian Cancer Metastasis" (2025–2028)
- NCI Key Personnel: "Precision use of radiation for in situ cancer immunization" (2025–2027)
- Breast Cancer Research Foundation Co-Investigator & Key Personnel: multi-year biomarker optimization studies (2024–2028)
- US Department of Defense Co-Investigator: extending CDK4/6 inhibitor efficacy via γδ T-cell targeting (2022–2025)
- Starr Cancer Consortium & NCI Co-PI/Co-I: microbiome-immunoglobulin G interplay in cancer progression (2023–2025)
Laboratory & Collaborations
Dr. Zhou maintains an active wet-lab and translational team at Weill Cornell, collaborating with radiation oncologists, medical oncologists, immunologists, and bioinformaticians. Multi-institutional consortia facilitate clinical trial accrual and high-dimensional data integration, ensuring rapid translation of preclinical findings into early-phase human studies.
